Slipped Capital Femoral Epiphysis Associated with Endocrinopathy: A Narrative Review.

JBJS Rev · Feb 07 2022 · Review

Shaw KA, Shiver AL, Oakes T, Fletcher ND

Dwight D. Eisenhower Army Medical Center, Fort Gordon, Georgia

SUMMARY — THE REDUCTIONSCFE is linked to endocrine disorders; presentation before age 10 or after 16 with height under the 10th percentile flags children for endocrine testing, and unilateral cases warrant prophylactic contralateral fixation.

Abstract, as published

»: Slipped capital femoral epiphysis (SCFE) has a well-documented association with underlying endocrine conditions, including thyroid hormone aberrations and parathyroid dysfunction.

»: Recombinant growth hormone therapy has also been identified as a risk factor for the development of SCFE.

»: Presentation before their 10th birthday or after their 16th birthday along with height of <10th percentile are reliable risk factors for identifying children with an SCFE who are at a heightened risk for an underlying endocrinopathy and can been used to guide selective laboratory testing.

»: Patients with unilateral SCFE presentations with an underlying endocrinopathy are at a heightened risk for contralateral slip development and should be treated with prophylactic fixation.

Read the article: PubMed · Publisher (DOI)

Featured in the 2026-10-16 issue.

← Preoperative ultrasound in pediatric supracondylar fracture-r…Sagittal Alignment in Adolescent Idiopathic Scoliosis with Ma… →

The Reduction is a free email digest of newly published orthopaedic literature — a handful of new papers in the subspecialties you choose, each summarized like this one. Subscribe free or browse the archive.